Patient, nurse and physician preferences: Final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or On-body injector (OBI) in cancer patients 5. November 2020 M. Metz, D. Semsek, G. Rogmans, U. Hutzschenreuter, T. Fietz, J. Harde, S. Zacharias, C. Hielscher, A. Lorenz, M.-O. Zahn, D. Guth, S. Grebhardt, C. Fichter, K. Potthoff, 2020. Download Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Link, H.,, Illerhaus, G., Martens, U. M., Salar, A., Depenbusch, R., Köhler, A., Engelhardt, M., Mahlmann, S., Zaiss, M., Lammerich, A., Bias P., Buchner, A. Weiterlesen First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial Staehler, M, Panic, A, Goebell, PJ, Merling, M, Potthoff, K, Herrmann, E, de Geeter, P, Vannier, C, Hogrefe, C, Marschner, N, Grünwald, V, 2020. Int… Weiterlesen